TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07668518: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Ranging, Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics and Early Efficacy of Inhaled KIT2014 Over 7 Days of Treatment in Pat

Sponsor: Kither Biotech Srl · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,712,740

Rescue Site Savings

+$3,104,200

Unlock Full NCT07668518 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07668518 Rescue Dossier →